Rewind Therapeutics

Rewind Therapeutics develops first-in-class therapeutics designed to re-initiate the process of remyelination in patients suffering from major debilitating diseases such as multiple sclerosis, optic neuritis, or nerve injuries. A common feature of these illnesses is the loss of the natural myelin sheath, a cover protecting and nurturing the nerves. Repairing or re-installing this sheath, known as remyelination, is a crucial factor for halting or even curing these diseases. The company's team has extensive research and development expertise and a strong patent estate for developing novel remyelination therapeutics.